Archive · 5 Jun 2025
Dr. Reddy’s and Alvotech to Develop Cancer Drug Biosimilar
Imagine a team of scientists, Dr. Reddy’s and Alvotech, is working together to create a copycat version, called a biosimilar, of a super important medicine named Keytruda, used to fight different types of cancer.
Keytruda, made by Merck, is a very successful drug.
Dr. Reddy’s and Alvotech will share the work of developing the medicine, making it, and selling it all over the world.
This team-up is expected to speed things up and make the biosimilar available to more people, focusing on treatments that help the body fight cancer.
Dr. Reddy’s and Alvotech will co-develop and commercialize a biosimilar for Keytruda.
The collaboration includes joint responsibility for development and manufacturing.
Each company will have the right to market the product globally.
The partnership aims to speed up development and expand global reach.
Keytruda is a cancer treatment with $29.5 billion in worldwide sales in 2024.
- Who
- Dr. Reddy’s Laboratories and Alvotech.
- What
- Co-development, manufacture, and commercialization of a Keytruda biosimilar.
- When
- June 5, 2025
- Where
- Global markets.
- Why
- To speed up development and expand global reach of a biosimilar for cancer drug Keytruda.
- Companies Involved
- Dr. Reddy’s Laboratories, Alvotech, and Merck
- Drug
- Biosimilar candidate to Keytruda (pembrolizumab)
- Purpose
- Co-development, manufacture, and commercialization of a biosimilar
- Keytruda's 2024 Sales
- $29.5 billion
- Agreement Date
- June 5, 2025